Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Jhaveri KL, et al. Among authors: bromberg jf. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283132 Free PMC article.
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2007 Jan 1;13(1):223-7. doi: 10.1158/1078-0432.CCR-06-1731. Clin Cancer Res. 2007. PMID: 17200358 Clinical Trial.
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. Fornier MN, et al. Ann Oncol. 2011 Dec;22(12):2575-2581. doi: 10.1093/annonc/mdr018. Epub 2011 Mar 15. Ann Oncol. 2011. PMID: 21406471 Free PMC article. Clinical Trial.
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.
Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. Dunphy MPS, et al. Among authors: bromberg j. Radiology. 2018 May;287(2):667-675. doi: 10.1148/radiol.2017162610. Epub 2018 Jan 31. Radiology. 2018. PMID: 29388903 Free PMC article. Clinical Trial.
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN. Morris PG, et al. Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15. Clin Breast Cancer. 2018. PMID: 29680193 Free PMC article. Clinical Trial.
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schöder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, Larson SM. Dunphy MPS, et al. Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4. Clin Cancer Res. 2020. PMID: 32366671 Free PMC article. Clinical Trial.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Wang DG, et al. Among authors: bromberg jf. Breast Cancer Res Treat. 2020 Aug;183(1):227-237. doi: 10.1007/s10549-020-05726-y. Epub 2020 Jun 29. Breast Cancer Res Treat. 2020. PMID: 32613539 Free PMC article.
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, Quigley EA, Haliasos HC, Moy AP, Schram AM, Bromberg J, Funt SA, Voss MH, Drilon A, Hellmann MD, Comen EA, Narala S, Patel AB, Wetzel M, Jung JY, Leung DYM, Lacouture ME. Barrios DM, et al. Ann Oncol. 2021 Jun;32(6):736-745. doi: 10.1016/j.annonc.2021.02.016. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33667669 Free PMC article.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Walsh EM, et al. Breast Cancer Res Treat. 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20. Breast Cancer Res Treat. 2022. PMID: 35986801 Free PMC article.
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Scott JM, Lee J, Herndon JE, Michalski MG, Lee CP, O'Brien KA, Sasso JP, Yu AF, Rowed KA, Bromberg JF, Traina TA, Gucalp A, Sanford RA, Gajria D, Modi S, Comen EA, D'Andrea G, Blinder VS, Eves ND, Peppercorn JM, Moskowitz CS, Dang CT, Jones LW. Scott JM, et al. Among authors: bromberg jf. Eur Heart J. 2023 Dec 7;44(46):4878-4889. doi: 10.1093/eurheartj/ehad085. Eur Heart J. 2023. PMID: 36806405 Free PMC article. Clinical Trial.
93 results